Multiple Sclerosis. Everything you need to know

On "Active Demyelination Lesions" on MRI Results

Today, it’s hard to believe, but 40 years ago, clinical practice possessed zero technology capable of visualizing what was happening inside a living brain. A person experiencing strange neurological symptoms would visit a doctor, undergo a long, tedious physical exam, and head home completely stripped of a definitive diagnosis. There were no McDonald criteria, no contrast enhancement, no "demyelination lesions"—or rather, they existed, but you could only find them during an autopsy. Before the arrival of MRI, a patient could feel systematically unwell for years without any way to map the structural warfare unfolding inside their skull.

One of the first to map strange neurological symptoms to physical changes in the brain was Jean-Martin Charcot. In 1868, he observed a patient presenting with tremors, nystagmus, and slurred speech. After her death, he conducted an autopsy and discovered characteristic "plaques" scattered through the brain's white matter. It was Charcot who coined the term scleróse en plaques—multiple sclerosis—and hypothesized that a hidden brain pathology was pulling the strings behind the outward symptoms. This launched a century-long era where MS was diagnosed entirely without MRIs, without spinal fluid analysis, and without any instrumental confirmation. A diagnosis was assembled purely from symptoms, their timeline, and the physician's clinical intuition. For decades, multiple sclerosis remained a "diagnosis of exclusion"—and the echoes of this strategy still form the bedrock of international diagnostic protocols today.

The first successful attempt to systemize this guesswork came in 1965 with the introduction of the "Schumacher criteria." According to these rules, a diagnosis could only be made if a patient experienced at least two relapses, each lasting more than 24 hours and separated by an interval of at least one month. Doctors also had to find objective neurological signs of damage in at least two separate areas of the central nervous system. The patient’s age had to sit strictly between 10 and 50, and any alternative explanations for the symptoms had to be completely ruled out. These criteria heavily prioritized the value of a physical exam and clinical observation over laboratory data, demanding a massive level of qualification, experience, and a willingness to monitor a patient over long stretches of time.

Without an MRI, a diagnosis was assembled literally "by eye." Everything hinged on the doctor’s ability to track and interpret subtle clinical cues: nystagmus, reflex asymmetries, pathological babinski signs, coordination, gait, and sensory maps. Any single detail could turn out to be the master key, but only when framed by the total clinical picture and how it shifted over time. Physicians had to know their patients practically intimately, not just as charts—otherwise, tracking the slippery dynamics of the disease was impossible.

An audit rarely wrapped up in a single visit; observation stretched across months or even years. A doctor had to recall and contrast today’s symptoms against how the patient presented six months or a year ago, ideally factoring in variables like weather, fatigue, stress, and other ambient triggers. Finding multiple sclerosis in a perfectly healthy person was incredibly easy; missing the disease entirely was just as easy; and objectively proving or disproving either was flat-out impossible. Naturally, a system wrapped in so much subjectivity and individual bias had zero chance of long-term stability: it simply left too much room for human error.

It wasn't until the late 1960s that the first genuine biomarker emerged: "oligoclonal bands" in the cerebrospinal fluid. Spotting OCBs offered the first concrete proof of a specific, localized inflammation within the CNS linked to multiple sclerosis. Before this breakthrough, the diagnosis was entirely "clinical"—meaning it was born strictly out of the doctor's office. Once science gained the ability to isolate intrathecal (intra-brain) antibody synthesis from the body's general immune response, MS diagnostics took a massive leap forward—oligoclonal IgG bands were detected in 95% of patients with genuine MS.

Yet, this first attempt to lock down the system ran into two distinct brick walls. First of all, harvesting cerebrospinal fluid via a lumbar puncture is an incredibly unpleasant procedure; it isn't 100% safe and frequently brings prolonged side effects. The second problem multiplies the first: roughly 10% of spinal fluid analyses yield a false negative.

A 10% margin of error is a massive vulnerability when dealing with a life-altering diagnosis. It threw physicians right back into a corner where clinical intuition and gut feeling carried more weight than laboratory data. What do you do if you are a young doctor facing a patient whose symptoms resemble MS but don't quite fit the textbook? What if the manual says one thing, but the latest revision of clinical guidelines says another? What if the spinal tap comes back completely clean, but the clinical mapping screams sclerosis? What do you do if you are only 70% certain, but the patient demands a definitive label and refuses to leave without one? Or conversely, what if the patient views MS as a death sentence, and you can't give them a straight "yes" or "no"?

The arrival of MRI didn’t just trigger a technological revolution—it fundamentally inverted the nature of diagnostics. Suddenly, "demyelination lesions" and "multiple sclerosis" could be visualized on a screen, which drastically simplified a doctor's workflow. The journey from the first experimental brain scan in 1981 to a fully standardized framework took exactly twenty years: in 2001, the McDonald criteria were adopted, legally equating the appearance of white spots on a tomograph to actual, physical clinical attacks.

On December 29, 1972, the captain and first officer of Eastern Airlines Flight EA-401 spent nine consecutive minutes trying to figure out why a tiny green nose-gear indicator light wouldn’t turn on. They yelled at each other, twisted the lightbulb, argued, called maintenance, and at some point, someone accidentally bumped the yoke. This bumped the autopilot out of altitude-hold mode, quietly drifting the aircraft off course. The plane crashed straight into the Florida Everglades, killing 101 out of 176 people on board—solely because the crew fixated on a single blinking bulb and trusted their automated instruments over reality. The cockpit of an aircraft that spent 9 minutes falling into a swamp held three highly qualified professionals, and all of them chose to trust the computer over their own senses. I urge you to look this up yourself—unfortunately, the "EA-401 crash in the Everglades" is a matter of historical fact.

Why bring this up? Automation is fantastic, but only if the system is structurally incapable of making mistakes. How often do automated systems fail? Early Tesla autoplots regularly plowed into parked vehicles. In 2003, an American Patriot missile battery operating in fully automated mode misidentified a British Tornado fighter jet as a hostile target and blew it out of the sky, killing the pilot and navigator. In 2010, high-frequency trading bots triggered a flash crash on the US stock market based on a false data loop—the market hemorrhaged billions in minutes. In 2020, Medtronic’s automated insulin delivery systems started glitching, throwing patients worldwide into severe hypo- or hyperglycemia. In every single instance, a standalone, isolated calibration error transformed into a systemic catastrophe because human operators stopped cross-checking the machines. With MS diagnostics via MRI, the situation turned out even worse: the calibration error was hardcoded into the standard operating procedure, creating a dangerous illusion of a stable and flawless diagnostic grid.

The contrast agents used in MRI scans are almost entirely built on compounds of gadolinium—a heavy, paramagnetic metal. Their actual job description has nothing to do with "detecting multiple sclerosis," "showing demyelination," or "measuring how sick a patient is." Gadolinium’s actual role is far more mundane: contrast enhancement simply maps zones where the blood-brain barrier has been structurally compromised. When the barrier inflames and turns porous—which happens during MS, brain tumors, infections, physical trauma, and an array of other pathologies—gadolinium molecules leak out into the brain tissue, making those spots burn bright on T1-weighted scans.

A structural breach of the blood-brain barrier occurs across a massive spectrum of conditions—strokes, angiomas, vasogenic edema, vasculitis, trauma, and post-traumatic inflammation. You see the exact same leaks in other autoimmune brain conditions, like systemic lupus erythematosus, sarcoidosis, and Behcet's disease. Furthermore, contrast-accumulating lesions are classic markers for radiation necrosis, post-surgical artifacts, the active phase of progressive multifocal leukoencephalopathy, and various granulomatous processes. Bottom line: bright spots on an MRI screen do not "show multiple sclerosis" and do not confirm a diagnosis. Contrast merely flags a leaky brain barrier, which can be caused by dozens of entirely distinct diseases.

The statistical probability that burning MRI lesions are genuinely tied to multiple sclerosis depends entirely on the clinical context: according to PubMed data, in specialized neurological centers auditing patients with high clinical suspicion of MS, about 50% to 70% of these hotspots are indeed the byproduct of demyelination. In the general population undergoing standard, routine scans, that figure plummets to 10–20%. This is exactly why the mere presence of lesions means nothing; their value hinges entirely on how they map against the total clinical profile.

The healthcare grid, like any massive bureaucratic machine, always moves toward equilibrium—not because it leads to objective truth, but because it streamlines standard operating procedures. When an MRI display throws up a picture full of white spots and a doctor faces a patient with vague, matching complaints, the path of least resistance is to write an equation: "burning lesions = multiple sclerosis." It’s faster, simpler, cleaner, and most importantly, it spares the physician from diving into complex differential diagnosis. Systems balance themselves through these exact shortcuts: an overworked doctor, buried under regulatory metrics and endless charts, stops hunting for absolute truth and settles for a functional compromise. The patient arrives demanding a label, and the presence of glowing spots allows the physician to stop treating MS as a rigorous "diagnosis of exclusion" and instead deploy it as a "catch-all label."

This is one of the foundational paragraphs of this book: if your diagnosis was slapped on based on a random MRI scan you were sent to after a brief, temporary bout of weird symptoms, and sclerosis hasn't bothered you once in the years since, you need to stop and think. No, your health isn't holding because "the interferon is working"—it is entirely possible that you never had multiple sclerosis in the first place. Yes, that is a quite possible—even if the diagnosis came from a doctor you trust unconditionally.

The misdiagnosis of multiple sclerosis is a shockingly common event: for example, in 2019, Marwa Kaisey and Nancy Sicotte tracked 241 labeled MS patients in the US, and discovered the diagnosis was flat-out wrong in 18% of cases—that’s 43 real people. It’s crucial to understand that the researchers only overturned a diagnosis when they were 100% certain it was completely bogus; how many borderline cases of overdiagnosis Kaisey and Sicotte missed is something we will unfortunately never know. What did the investigators expose? First and foremost, they proved that when these bogus labels were minted, the lumbar puncture was systematically ignored: it was either never performed at all, or its negative result was tossed into the trash as "non-informative."

On "Non-Informative" Lumbar Punctures

As you have already realized, multiple sclerosis is surrounded on all sides by deep-seated misconceptions, but nowhere does this diagnostic confusion manifest as clearly as in the analysis of cerebrospinal fluid. This is where the main diagnostic bottleneck lives—overgrown, tangled, and multi-layered. I will try to lay it out so that you can actually understand it, which means I will simplify a few things and use a couple of non-ideal analogies. It won't be effortless, but if you look at it closely, a lot of light will be shed on the myths surrounding the lumbar puncture.

To start, every single one of us carries cerebrospinal fluid—CSF. It bathes the brain and spinal cord, and it is structurally insulated from the rest of the body by a specialized filter: the blood-brain barrier. If the barrier gets damaged and begins letting background noise through, it is always a reason to investigate, but it is far from an exclusive marker for MS. A breach in the barrier can be triggered by absolutely anything—infections, physical trauma, localized inflammation, and a massive spectrum of autoimmune conditions.

When the blood-brain barrier is compromised, lymphocytes drift into the CSF. Don't panic—in and of itself, this isn't particularly dangerous. White blood cells are found in the spinal fluid of perfectly healthy people too. Most of the time, they are simply doing their standard janitorial work: hunting for viruses, bacteria, cellular debris, and other junk. After a while, the barrier patches itself up, and the situation returns to baseline—including on your MRI scans. "Burning lesions" appear precisely because of a breached barrier, and as soon as it heals, they dim or stop glowing altogether.

A single microliter of blood holds anywhere from 1,000 to 4,000 lymphocytes; a single liter holds 1 to 4 billion; and the entire bloodstream carries between 5 and 20 billion. This brings us to another massive misconception: lymphocytes are called blood cells, but the vast majority of them live completely outside the blood. The bulk of the population is dug into the lymph nodes, the spleen, the thymus, mucous membranes, and other strategic hubs of the immune grid. The total number of lymphocytes in the human body is estimated between 1 and 2 trillion, making the bloodstream just a tiny fraction of their massive collective force. During an active infection, the body can ramp up production exponentially through clonal division, causing their numbers to surge in a flash.

How often are defective lymphocytes manufactured? Constantly. But normally, they are wiped out immediately through built-in security protocols that force a rogue cell to commit cellular hara-kiri. Sometimes, however, a flawed T-cell slips through every layer of defense, survives, and takes up residence in a lymph node—becoming a ticking time bomb for an autoimmune reaction. If that T-cell subsequently manages to force its way into the brain tissue and mistakes myelin for an invader, it sounds a chemical siren and calls for backup. Up to a quarter of that backup force is made up of B-lymphocytes, which soon mutate into plasma cells upon arrival.

How many plasma cells actually set up antibody-manufacturing hubs inside the brain tissue of MS patients? Anywhere from a few hundred to several thousand, and they typically descend from just a few dozen clonal lines of B-lymphocytes. This does not mean only a few dozen physical cells are participating in the firefight; rather, it refers to the distinct variants of IgG antibodies—the specific configurations of the BCR receptors on the B-cells that breached the brain. Each of these antibody profiles can be printed by thousands of descendants of a single root B-cell, since B-lymphocytes multiply aggressively, scaling up their immunoglobulin assembly lines. Thus, while the number of distinct clones is discrete, the intensity of their manufacturing output can scale massively. The numbers here are staggering: a single standalone plasma cell can pump out roughly 2,000 antibodies every single second.

The average adult body carries about 150 ml of cerebrospinal fluid. During a standard lumbar puncture, doctors draw roughly 10 ml—about 6% of the total volume, which is drastically higher than the 0.1–0.2% sample taken for a routine blood test. Isolating the specific antibody synthesis profile requires only 2 to 3 ml; the rest goes to cytological, biochemical, and infectious panels. The real bottleneck of the spinal tap lies elsewhere: CSF requires exceptionally delicate handling and rapid transport. Even at the correct temperature, prolonged transit times trigger the breakdown of blood cells caught in the fluid. Outside a living organism, these cells die rapidly; their internal protein structures burst outward, clotting the test gel and rendering the result completely unreadable. By the way, don't sweat the 6% loss: your brain replenishes CSF continuously and rapidly, manufacturing about half a liter of this fluid every single day.

Now, let's look at the test itself. To measure how many B-cell clones are printing antibodies and tracking their manufacturing speed, we have to sort them out somehow. Laboratories use a method called isoelectric focusing—a specialized technique that separates immunoglobulins based on their isoelectric point, which is the exact pH level where the antibody's electrical charge drops to zero. Essentially, the CSF is poured onto a gel matrix with a built-in pH gradient. Antibodies from different clonal families lose their charge at different acidity levels, settling across the gel in visible "oligoclonal bands" that map back to specific B-cell lineages. Every single band is the footprint of a distinct clan of autoimmune hunters printing antibodies modeled on their progenitor's receptor.

I think it's time to pause and roll out the analogy I promised at the start. Picture the CSF as an active combat zone, and the activated autoimmune B-lymphocytes as soldiers armed with machine guns. Each soldier's gun is loaded with a unique color of tracer ammunition. These B-cells can multiply by splitting, but the guns and tracers carried by their copies remain identical to the original, which means the spent cartridges—the antibodies—left on the battlefield carry the exact same color signature. If you collect and sort these cartridges across different sectors of the field, you can calculate exactly how aggressively a specific soldier and his clone platoon were firing their weapons.

Before drawing any macro conclusions, it's worth noting that in about 10% of cases, the biological sample degrades and fails to throw up clean, visible bands. This is almost always a logistics issue: the sample hits the lab spoiled because lymphocytes ruptured in transit, bleeding their internal protein noise into the fluid and clogging the gel, making the matrix unreadable. Pay close attention: this happens in no more than 10% of cases, yet this exact variable is why so many neurologists repeat the mantra that "the spinal tap is non-informative." The reality is uglier: the majority of them have never bothered to look into how the lab analysis is actually conducted; they simply echo a position widely accepted within their professional echo chamber. For context: routine tests for streptococcus, staphylococcus, herpes, chlamydia, and tuberculosis show an identical false-negative rate. Have you ever heard a doctor claim that a tuberculosis test is "non-informative"?